Savara Inc Business Acquisition, Pro Forma Revenue
Savara Inc (SVRA) reported Business Acquisition, Pro Forma Revenue of $94.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2017-11-08
- Savara Inc business acquisition, pro forma revenue for the quarter ending 2017-09-30 was $93.91K.
- Savara Inc business acquisition, pro forma revenue for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- Savara Inc business acquisition, pro forma revenue for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- Savara Inc business acquisition, pro forma revenue for the quarter ending 2013-12-31 was $5.83M.
- Savara Inc business acquisition, pro forma revenue for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- Savara Inc business acquisition, pro forma revenue for fiscal 2013 was $7.30M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | $93.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $94.00K 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $94.00 10-Q · filed 2017-08-09 | ||||
| 2016-12-31 | $528.00K 10-Q · filed 2017-11-08 | $528.00 10-Q · filed 2017-08-09 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-24 | $0.00 derived: sum of 2 quarters · filed 2015-03-24 | $0.00 10-K · filed 2015-03-24 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $0.00 10-Q · filed 2014-10-31 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | ||||
| 2013-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-24 | $6.40M derived: sum of 2 quarters · filed 2015-03-24 | $6.91M derived: sum of 3 quarters · filed 2015-03-24 | $7.30M 10-K · filed 2015-03-24 | |
| 2013-09-30 | $564.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $1.07M derived: sum of 2 quarters · filed 2014-10-31 | $1.47M 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | $508.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $906.83K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $397.86K 10-Q · filed 2014-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |